entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 00:59:24 - browse：228

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Prime Medicine, Myeloid Therapeutics clash over genome

WSS

Why health care costs have stayed mostly flat since 2010

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Three trends to watch in biotech in 2024

Virtual care provider acquires bankrupt Pear's prescription apps

Keeping primary care docs in field isn't impossible, says AAFP CEO

Prime Medicine, Myeloid Therapeutics clash over genome

explore

entertainment

focus

Medical leaders decry Supreme Court decision on affirmative action

Pancreatic cancer early detection could be helped by AI

Dobbs anniversary: the lost opportunity of abortion as health care

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Cancer drug shortages should be causing more outrage

Vertex non

State Dept. review finds Biden bears some blame for Afghanistan failures

Editas, Vertex strike deal on CRISPR

Medical records are filled with copy

The Affordable Care Act has saved billions in health care costs

Wikipedia

Readout Newsletter: The latest on Novavax, Merck, Bluebird

CRISPR gene editing developments we’re watching in 2024

Virtual care provider acquires bankrupt Pear's prescription apps

Venture capital firm's plans to take over Akron hospital face hurdles

White House pharmacy plagued with problems, investigation finds

Humana’s losses in Medicare Advantage tank its stock

explore

hotspot

leisure time

hotspot